Schonfeld Strategic Advisors LLC Has $273,000 Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Schonfeld Strategic Advisors LLC lowered its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 89.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,657 shares of the company's stock after selling 166,806 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in Syndax Pharmaceuticals were worth $273,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in Syndax Pharmaceuticals in the fourth quarter valued at approximately $26,000. Virtus ETF Advisers LLC lifted its stake in Syndax Pharmaceuticals by 18.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after buying an additional 827 shares during the last quarter. Cape Investment Advisory Inc. lifted its stake in Syndax Pharmaceuticals by 157.1% in the fourth quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock valued at $85,000 after buying an additional 3,927 shares during the last quarter. KBC Group NV lifted its stake in Syndax Pharmaceuticals by 104.8% in the fourth quarter. KBC Group NV now owns 6,954 shares of the company's stock valued at $92,000 after buying an additional 3,559 shares during the last quarter. Finally, Optimize Financial Inc purchased a new stake in Syndax Pharmaceuticals in the fourth quarter valued at approximately $152,000.

Syndax Pharmaceuticals Stock Performance

Shares of NASDAQ SNDX traded up $0.10 during trading on Friday, reaching $9.05. The stock had a trading volume of 2,954,265 shares, compared to its average volume of 1,725,031. Syndax Pharmaceuticals, Inc. has a one year low of $8.58 and a one year high of $25.07. The stock has a market cap of $778.73 million, a PE ratio of -2.49 and a beta of 0.82. The firm's 50 day moving average price is $12.10 and its two-hundred day moving average price is $14.03.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.06. The business had revenue of $20.04 million during the quarter, compared to the consensus estimate of $15.88 million. During the same period in the previous year, the company posted ($0.85) EPS. The company's revenue for the quarter was up 1900.0% compared to the same quarter last year. On average, research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Guggenheim reiterated a "buy" rating and issued a $32.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 6th. Scotiabank increased their price objective on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research report on Tuesday, May 6th. Citigroup cut their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. JPMorgan Chase & Co. increased their price objective on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research report on Thursday, March 20th. Finally, HC Wainwright restated a "buy" rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.91.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).